Group 1 - The core point of the article is that TianKang has received a drug registration certificate for Methimazole tablets from the National Medical Products Administration, which is a significant regulatory milestone for the company [1] - TianKang's revenue composition for the year 2024 is as follows: 61.1% from pharmaceutical agency, 37.28% from pharmaceutical manufacturing, 1.51% from pharmaceutical technology services, and 0.12% from other businesses [1] - As of the report, TianKang's market capitalization stands at 11.7 billion yuan [1] Group 2 - The article also highlights a concerning trend in the pharmaceutical industry regarding the abuse of prescription drugs, specifically citing the first reported case of pregabalin addiction in China [1] - It mentions vulnerabilities in online platforms that allow the purchase of medications without proper medical records, raising questions about regulatory oversight [1] - The classification of such drugs and the need for scientific evaluation regarding their regulation is emphasized [1]
泰恩康：“甲巯咪唑片”取得注册证